Sam Chun Dang Pharm Co., Ltd. (000250) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Sam Chun Dang Pharm Co., Ltd. (000250:KRX), powered by AI.

Current Price
₩266,000
P/E Ratio
1185.8
Market Cap
6.2T
Sector
Common Stock
What is the Sam Chun Dang Pharm Co., Ltd. stock price forecast?

Sam Chun Dang Pharm Co., Ltd. is currently trading at ₩266,000. View real-time AI analysis on Alpha Lenz.

What is Sam Chun Dang Pharm Co., Ltd. insider trading activity?

View the latest insider trading data for Sam Chun Dang Pharm Co., Ltd. on Alpha Lenz.

What is Sam Chun Dang Pharm Co., Ltd.'s P/E ratio?

Sam Chun Dang Pharm Co., Ltd.'s P/E ratio is 1185.8.

Sam Chun Dang Pharm Co., Ltd.

KRX · 000250
₩266,000+4,500(+1.72%)Market closedKRX regular session 09:00–15:30 KST
Ask about Sam Chun Dang Pharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Sam Chun Dang Pharm Co., Ltd. trades at a P/E of 1185.8 (premium valuation) with modest ROE of 1.9%.

Ask for details

Company Overview

Sam Chun Dang Pharm Co., Ltd. is a notable pharmaceutical company involved in the research, development, and production of various healthcare solutions. Founded in South Korea, the company focuses on creating a diverse array of pharmaceutical products that cater to the healthcare needs of a broad spectrum of patients. Their portfolio includes over-the-counter drugs, prescription medications, and a range of health supplements, demonstrating their commitment to improving public health and optimizing therapeutic outcomes. By participating actively in the pharmaceutical industry, Sam Chun Dang Pharm Co., Ltd. contributes significantly to the accessibility and availability of essential medications across regional and global markets. The company consistently invests in innovation and manufacturing excellence, ensuring compliance with international regulatory standards and thereby enhancing its market reputation. Its role in the healthcare sector is pivotal, as it addresses critical medical needs and supports the overall advancement of medical sciences.

CEO전인석
SectorCommon Stock
IndustryCommon Stock
0

Company Statistics

FY 2025

Profile

₩6,239,687,552,000Market Cap
₩231,805,277,730Revenue
23.46MShares Out
0Employees

Margins

47.18%Gross
9.72%EBITDA
3.65%Operating
5.40%Pre-Tax
5.19%Net

Valuation

1185.84P/E
22.61P/B
26.92EV/Sales
279.69EV/EBITDA
-125.31P/FCF

Growth (CAGR)

9.34%Rev 3Yr
6.80%Rev 5Yr
-11.52%Op Inc 3Yr
8.92%Op Inc 5Yr
10.85%Net Inc 3Yr
9.93%Net Inc 5Yr

Returns

2.23%ROA
1.94%ROE
2.50%ROIC

Financial Health

₩95,943,976,390Cash & Cash Equivalents
₩101,694,182,390Net Debt
54.36%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Sam Chun Dang Pharm Co., Ltd. (ticker: 000250) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $6.2T.

The current price is ₩266,000 with a P/E ratio of 1,185.84x and P/B of 22.61x.

ROE is 1.94% and operating margin is 3.65%. Annual revenue is $231.8B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Sam Chun Dang Pharm Co., Ltd. (000250) Stock Forecast 2026 ₩266,000 — Price, Financials & Analyst Targets | Alpha Lenz